The through-line of Suchul Jang's career is small enough to fit inside a cell. For most of two decades he has worked with the machinery bodies already use to move things around and clean things up - vesicles, receptors, the quiet logistics of biology - and asked a version of the same question each time. If the cell already knows how to do this, can we teach it to do a little more?
That question started in a laboratory at Pohang University of Science and Technology, where Jang earned both his bachelor's degree and his Ph.D. It carried him to Sweden, then to Cambridge, Massachusetts, and now to a Boston office where he serves as Chief Executive Officer of Illimis Therapeutics USA. The company behind him is based in Seoul. The science in front of him is aimed at one of the hardest targets in medicine: the aging brain.
01 / OriginsThe vesicle that followed him around
During his doctoral program, Jang invented exosome-mimetic nanovesicles - engineered particles designed to carry anti-cancer drugs to where they could work. Exosomes are the tiny packages cells release to communicate with one another. They are also, it turns out, a very good delivery vehicle if you can learn to build and load them. That early work set the theme for everything that came next.
He took it abroad, joining the group of Jan Lotvall at the University of Gothenburg for postdoctoral training. Lotvall is one of the founding figures of the extracellular vesicle field, and the lab was a natural home for someone whose scientific instinct kept returning to the same object. By the time Jang moved to the United States, the exosome was less a research interest than a specialty.
02 / CodiakFrom bench to clinical candidate
The place that specialty found its fullest expression was Codiak BioSciences, a clinical-stage company built entirely around exosome therapeutics. Jang did not arrive as an executive. He came in as a scientist and worked his way up - Scientist, Senior Scientist, Associate Director, and eventually Director of Preclinical & Biomarkers and Head of In Vivo Pharmacology. Titles are a crude measure of a career, but the shape of that climb tells you something: he earned the leadership by doing the work first.
Along the way he co-invented exoSTING, Codiak's first clinical candidate. exoSTING is an engineered exosome loaded with a potent agonist of the STING pathway, designed to switch on an immune response inside a tumor while sparing the rest of the body. The preclinical program showed a large jump in potency compared with a free drug, and the work was published in the Nature journal Communications Biology. He also helped advance other programs in the pipeline, including exoIL-12, exoASO-STAT6, and exoVACC.
By the numbers, Jang is a builder of intellectual property: more than 20 patents and 36 published articles. But the more useful way to read that record is as consistency. The papers and the patents circle the same set of ideas - delivery, targeting, and the machinery cells use to handle their own traffic - refined over years rather than scattered across fashions.
03 / The pivotWalking into the brain
After Codiak, Jang served as Senior Director of Biology at hC Bioscience, a company working on tRNA-based therapeutics - a different modality, another problem of getting biology to do something new. Then, in 2024, he made a move that looks unusual on paper. He joined Illimis Therapeutics not as a chief executive but as Chief of Staff to the company's CEO, Sanghoon Park.
It is worth sitting with that choice. A scientist with a clinical candidate to his name and a directorship behind him took a role defined by proximity rather than title. The logic becomes clear once you look at what Illimis is trying to do. Getting close to the mission first, and stepping up second, is a pattern that shows up again and again in people who end up running things well. By 2025 he had moved into the CEO seat at Illimis Therapeutics USA.
04 / The scienceLetting the brain clean up after itself
Illimis is built around a platform called GAIA - shorthand for Gas6-mediated Anti-Inflammatory Adaptor. The core idea borrows from the body's own cleanup crew. In the brain, a family of receptors known as TAM (Tyro3, Axl, and Mer) sits on the surface of glial cells and helps them recognize and clear debris. Gas6 is the natural ligand that flags that debris for removal.
GAIA is a bispecific fusion protein. One end grabs onto a target such as amyloid-beta. The other end is an engineered version of Gas6 that binds the TAM receptor. By holding both at once, the molecule brings the target and the cleanup machinery together and triggers the receptor to act - prompting the cell to engulf and clear the misfolded protein through phagocytosis. The design goal that matters most is what it avoids: doing this without the inflammation that has complicated other approaches.
How the GAIA platform is designed to work, simplified.
Why does the "quietly" part matter so much? Some of the field's most advanced anti-amyloid therapies carry a well-known complication known as ARIA - amyloid-related imaging abnormalities - which is tied to inflammation and vascular effects. Illimis frames its whole thesis around clearance that sidesteps that problem. The company describes GAIA as enabling inflammation-silent clearance of amyloid beta and the mitigation of ARIA risk. That is the pitch Jang carries into rooms in the United States.
The platform is not a single drug but a set of them. Illimis is developing candidates against three of the best-known misfolded proteins in neurodegeneration: amyloid-beta (ILM01, its lead program for Alzheimer's), tau (ILM02), and alpha-synuclein (ILM03). Beyond the brain, the company sees room to extend the same TAM biology into immune disorders.
05 / MomentumMoney and a large partner
Ideas in biotech need two things to move: capital and validation. In 2025, Illimis closed a Series B of 58 billion Korean won, roughly $42 million, drawing in a long roster of existing and new investors to push its GAIA-based pipeline forward and broaden into immune disease. The round lifted the company's reported total funding to around $65 million.
Reported funding and headcount. Bars are scaled for comparison, not to a common axis.
Validation arrived in a different form. In 2024, Illimis entered a research collaboration with Eli Lilly through the pharma giant's Catalyze360-ExploR&D program, working to advance the platform for neurodegenerative disease. Large companies do not lend their name to everyone, and a partnership like that reads as a signal about the science as much as a source of support.
06 / The operator-scientistWhat the path adds up to
Read Jang's resume in one line and it looks like a series of unrelated jumps: cancer exosomes, tRNA, and now Gas6 fusion proteins for the brain. Read it more slowly and it is one job done in three settings. Each time, the assignment has been to take a piece of the body's existing machinery and engineer it to solve a problem it was not solving on its own. The targets change. The habit of mind does not.
The role he holds now asks something the bench never did. Running the U.S. arm of a company headquartered on the other side of the world means translating - between a Seoul team and an American market, between deep science and the people who fund and partner with it. It is a job for someone who can speak both languages fluently, which is a fair description of a scientist who kept getting handed more to run.
The story is still early. The lead program is heading toward the clinic rather than through it, and the biggest claims about GAIA remain to be proven where it counts. But the person steering the American side of that effort has been circling the same idea since graduate school, patiently, one modality at a time. In a field that rewards both depth and reinvention, Suchul Jang has quietly built a case that you can have both.